Cullen/Frost Bankers, Inc. Avidity Biosciences, Inc. Transaction History
Cullen/Frost Bankers, Inc.
- $8.43 Billion
- Q3 2025
A detailed history of Cullen/Frost Bankers, Inc. transactions in Avidity Biosciences, Inc. stock. As of the latest transaction made, Cullen/Frost Bankers, Inc. holds 50 shares of RNA stock, worth $3,484. This represents 0.0% of its overall portfolio holdings.
Number of Shares
50Holding current value
$3,484% of portfolio
0.0%Shares
1 transactions
Others Institutions Holding RNA
# of Institutions
251Shares Held
119MCall Options Held
340KPut Options Held
145K-
Price T Rowe Associates Inc Baltimore, MD10.8MShares$753 Million0.03% of portfolio
-
Janus Henderson Group PLC London, X010.8MShares$751 Million0.16% of portfolio
-
Rtw Investments, LP New York, NY9.62MShares$670 Million4.2% of portfolio
-
Wellington Management Group LLP Boston, MA9.25MShares$645 Million0.05% of portfolio
-
Vanguard Group Inc Valley Forge, PA9.25MShares$645 Million0.0% of portfolio
About Avidity Biosciences, Inc.
- Ticker RNA
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 52,127,000
- Market Cap $3.63B
- Description
- Avidity Biosciences, Inc., a biopharmaceutical company, engages in the development of oligonucleotide-based therapies. It develops antibody oligonucleotide conjugates (AOC) that are designed to treat a range of serious diseases. The company's lead product candidate AOC 1001 is used for the treatment of myotonic dystrophy type 1, a rare monogenic...